Table 1 Description of included trials
n (%) | |
|---|---|
Year | |
2009 | 1 (1) |
2010 | 0 (0) |
2011 | 2 (1) |
2012 | 3 (2) |
2013 | 6 (4) |
2014 | 21 (15) |
2015 | 49 (36) |
2016 | 56 (41) |
Phase | |
3 | 48 (35) |
4 | 90 (65) |
Planned enrolment (median and range) | 135 (12–5000) |
Region of worka | |
Asia | 55 (40) |
Europe | 45 (33) |
North America | 46 (33) |
South America | 8 (6) |
Africa | 6 (4) |
Central America | 4 (3) |
Australia | 1 (1) |
Not reported | 6 (4) |
Trial design | |
Parallel | 125 (91) |
Crossover | 11 (8) |
Other | 2 (1) |
Type of intervention | |
Drug | 137 (92) |
Placebo | 83 (60) |
Active drug | 36 (26) |
Usual care | 1 (1) |
Other | 7 (5) |
Education or lifestyle | 3 (2) |
Nutrition | 6 (4) |
Device | 2 (1) |
Duration of follow-up (median and range)b | 24 (0–364) weeks |